Aptevo Therapeutics Statistics
Total Valuation
APVO has a market cap or net worth of $5.94 million. The enterprise value is -$11.05 million.
Important Dates
The next estimated earnings date is Wednesday, May 13, 2026, after market close.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
APVO has 1.18 million shares outstanding.
| Current Share Class | 1.18M |
| Shares Outstanding | 1.18M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +320.64% |
| Owned by Insiders (%) | 0.06% |
| Owned by Institutions (%) | 2.22% |
| Float | 1.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.29 |
| P/TBV Ratio | 0.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.82, with a Debt / Equity ratio of 0.27.
| Current Ratio | 3.82 |
| Quick Ratio | 3.57 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -234.61% and return on invested capital (ROIC) is -102.26%.
| Return on Equity (ROE) | -234.61% |
| Return on Assets (ROA) | -76.87% |
| Return on Invested Capital (ROIC) | -102.26% |
| Return on Capital Employed (ROCE) | -124.44% |
| Weighted Average Cost of Capital (WACC) | 7.05% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$786,879 |
| Employee Count | 33 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -98.62% in the last 52 weeks. The beta is 1.51, so APVO's price volatility has been higher than the market average.
| Beta (5Y) | 1.51 |
| 52-Week Price Change | -98.62% |
| 50-Day Moving Average | 5.63 |
| 200-Day Moving Average | 23.30 |
| Relative Strength Index (RSI) | 52.26 |
| Average Volume (20 Days) | 41,731 |
Short Selling Information
The latest short interest is 133,103, so 11.26% of the outstanding shares have been sold short.
| Short Interest | 133,103 |
| Short Previous Month | 112,000 |
| Short % of Shares Out | 11.26% |
| Short % of Float | 11.27% |
| Short Ratio (days to cover) | 1.46 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -26.31M |
| Pretax Income | -25.97M |
| Net Income | -25.97M |
| EBITDA | -26.07M |
| EBIT | -26.31M |
| Earnings Per Share (EPS) | -$82.30 |
Full Income StatementBalance Sheet
The company has $21.62 million in cash and $4.63 million in debt, with a net cash position of $16.99 million or $14.38 per share.
| Cash & Cash Equivalents | 21.62M |
| Total Debt | 4.63M |
| Net Cash | 16.99M |
| Net Cash Per Share | $14.38 |
| Equity (Book Value) | 17.38M |
| Book Value Per Share | 17.42 |
| Working Capital | 17.03M |
Full Balance SheetCash Flow
| Operating Cash Flow | -25.59M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 240,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -25.59M |
| FCF Per Share | -$21.66 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
